<DOC>
	<DOCNO>NCT00092274</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy HuMax-CD20 treatment Follicular Lymphoma ( FL ) .</brief_summary>
	<brief_title>Study HuMax-CD20 , New Drug Treat Early Stage Non-Hodgkin´s Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed refractory follicular lymphoma grade III Tumor verify CD20 positive CT scan showing demarcate lesion Previous treatment rituximab result less partial response Previous radioimmunotherapy Previous stem cell transplantation Received following treatment within 4 week prior enter study : 1 . Anticancer therapy 2 . Glucocorticosteroids unless less 10 mg prednisolone/day 3 . Radiotherapy Received Mitomycin C Nitrosoureas within 6 week prior enter trial HIV positivity Hepatitis B hepatitis C Uncontrolled chronic bacterial , fungal viral infection Other cancer disease , except certain skin cancer , cervix cancer breast cancer Certain serious medical condition , include kidney liver disease , psychiatric illness , stomach , lung , heart , hormonal , nerve blood disease WHO performance status 3 4 If participate another trial different new drug 4 week enter trial Current participation clinical study Pregnant breastfeed woman Women childbearing age unable unwilling use IUD hormonal birth control whole trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Non Hodgkin´s Lymphoma</keyword>
</DOC>